ARS Pharmaceuticals, Inc. (SPRY) · Aug 13, 2026 · Earnings

neffy is growing—but ARS just admitted the launch was overspending

In line — $33.7M revenue vs ~$32.0M consensus; EPS -$0.63 vs ~-$0.50 consensus

Q2 revenue topped expectations, but the EPS miss exposed heavy spending. ARS is pivoting from broad advertising to targeted prescribers and cutting cash costs.

The next major valuation test is clinical, not another routine quarter. Interim Phase 2b data for ARS-2 in chronic spontaneous urticaria is now expected in Q1 2027. The program could expand the platform into an area with no FDA-approved on-demand treatment for acute flares, but the filing provides no efficacy result yet; for now, it is an option value rather than delivered evidence. (Expanding the Intranasal Epinephrine Platform)

What to watch next

Interim CSU Phase 2b data, Q1 2027

Original filing on SEC EDGAR

More ARS Pharmaceuticals, Inc. news

neffy is growing—but ARS just admitted the launch was overspending | SPRY Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.